Evolutionary Genomics, Inc. (FNAM)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 | 7.94 Million USD | 8.37% |
| 2021 | 7.33 Million USD | 26.01% |
| 2020 | 5.81 Million USD | 27.14% |
| 2019 | 4.57 Million USD | 14.84% |
| 2018 | 3.98 Million USD | -0.27% |
| 2017 | 3.99 Million USD | -12.4% |
| 2016 | 4.56 Million USD | 1697.55% |
| 2015 | 253.75 Thousand USD | 1756.0% |
| 2014 | 13.67 Thousand USD | -82.51% |
| 2013 | 78.16 Thousand USD | 23.54% |
| 2012 | 63.26 Thousand USD | 29.48% |
| 2011 | 48.86 Thousand USD | 55.0% |
| 2010 | 31.52 Thousand USD | 18.59% |
| 2009 | 26.58 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q2 | - USD | 0.0% |
| 2023 Q1 | - USD | -100.0% |
| 2023 Q3 | - USD | 0.0% |
| 2022 Q2 | 7.86 Million USD | 0.48% |
| 2022 Q1 | 7.82 Million USD | 6.7% |
| 2022 FY | 7.94 Million USD | 8.37% |
| 2022 Q4 | 7.94 Million USD | 0.25% |
| 2022 Q3 | 7.92 Million USD | 0.82% |
| 2021 Q3 | 7.35 Million USD | 22.12% |
| 2021 Q2 | 6.02 Million USD | 2.12% |
| 2021 Q1 | 5.89 Million USD | 1.33% |
| 2021 FY | 7.33 Million USD | 26.01% |
| 2021 Q4 | 7.33 Million USD | -0.28% |
| 2020 Q3 | 4.62 Million USD | -6.18% |
| 2020 Q2 | 4.93 Million USD | 5.12% |
| 2020 Q1 | 4.69 Million USD | 2.49% |
| 2020 FY | 5.81 Million USD | 27.14% |
| 2020 Q4 | 5.81 Million USD | 25.78% |
| 2019 Q1 | 4.04 Million USD | 1.41% |
| 2019 Q2 | 4.54 Million USD | 12.49% |
| 2019 FY | 4.57 Million USD | 14.84% |
| 2019 Q3 | 4.54 Million USD | -0.03% |
| 2019 Q4 | 4.57 Million USD | 0.7% |
| 2018 Q1 | 3.99 Million USD | -0.01% |
| 2018 Q2 | 958.02 Thousand USD | -76.02% |
| 2018 FY | 3.98 Million USD | -0.27% |
| 2018 Q4 | 3.98 Million USD | 316.48% |
| 2018 Q3 | 956.83 Thousand USD | -0.12% |
| 2017 Q4 | 3.99 Million USD | -11.98% |
| 2017 Q2 | 4.52 Million USD | -4.7% |
| 2017 Q3 | 4.53 Million USD | 0.28% |
| 2017 Q1 | 4.75 Million USD | 4.14% |
| 2017 FY | 3.99 Million USD | -12.4% |
| 2016 Q4 | 4.56 Million USD | 46.95% |
| 2016 FY | 4.56 Million USD | 1697.55% |
| 2016 Q3 | 3.1 Million USD | 3.17% |
| 2016 Q2 | 3 Million USD | -0.39% |
| 2016 Q1 | 3.02 Million USD | 1090.34% |
| 2015 Q3 | 45.94 Thousand USD | 27.15% |
| 2015 FY | 253.75 Thousand USD | 1756.0% |
| 2015 Q4 | 253.75 Thousand USD | 452.27% |
| 2015 Q1 | 31.2 Thousand USD | 128.23% |
| 2015 Q2 | 36.13 Thousand USD | 15.81% |
| 2014 Q2 | 100.00 USD | -99.87% |
| 2014 FY | 13.67 Thousand USD | -82.51% |
| 2014 Q4 | 13.67 Thousand USD | 59.51% |
| 2014 Q1 | 79.06 Thousand USD | 1.15% |
| 2014 Q3 | 8571.00 USD | 8471.0% |
| 2013 Q2 | 73.64 Thousand USD | 12.62% |
| 2013 FY | 78.16 Thousand USD | 23.54% |
| 2013 Q4 | 78.16 Thousand USD | 3.41% |
| 2013 Q3 | 75.58 Thousand USD | 2.64% |
| 2013 Q1 | 65.39 Thousand USD | 3.36% |
| 2012 FY | 63.26 Thousand USD | 29.48% |
| 2012 Q2 | 57.88 Thousand USD | 2.98% |
| 2012 Q1 | 56.2 Thousand USD | 15.04% |
| 2012 Q3 | 60.01 Thousand USD | 3.69% |
| 2012 Q4 | 63.26 Thousand USD | 5.42% |
| 2011 Q1 | 38.72 Thousand USD | 22.83% |
| 2011 FY | 48.86 Thousand USD | 55.0% |
| 2011 Q4 | 48.86 Thousand USD | 5.01% |
| 2011 Q3 | 46.53 Thousand USD | 14.83% |
| 2011 Q2 | 40.52 Thousand USD | 4.65% |
| 2010 Q4 | 31.52 Thousand USD | 25.35% |
| 2010 FY | 31.52 Thousand USD | 18.59% |
| 2010 Q3 | 25.14 Thousand USD | 0.0% |
| 2009 Q4 | 26.58 Thousand USD | 0.0% |
| 2009 FY | 26.58 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| America Great Health | 4.82 Million USD | -64.677% |
| Ampio Pharmaceuticals, Inc. | 2.37 Million USD | -234.41% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | 79.588% |
| Biora Therapeutics, Inc. | 132.63 Million USD | 94.009% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -185.915% |
| Better Therapeutics, Inc. | 23.84 Million USD | 66.674% |
| Calithera Biosciences, Inc. | 8.28 Million USD | 4.085% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | 20.339% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | 69.833% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | 75.001% |
| Evelo Biosciences, Inc. | 69.43 Million USD | 88.556% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | 83.485% |
| Galera Therapeutics, Inc. | 157.32 Million USD | 94.95% |
| Innovation1 Biotech Inc. | 3.5 Million USD | -126.631% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | 62.679% |
| Molecular Templates, Inc. | 31.17 Million USD | 74.51% |
| Navidea Biopharmaceuticals, Inc. | 12.51 Million USD | 36.511% |
| NexImmune, Inc. | 5.08 Million USD | -56.279% |
| Orgenesis Inc. | 35.53 Million USD | 77.64% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | 51.88% |
| Point of Care Nano-Technology, Inc. | 266.41 Thousand USD | -2882.42% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -246.163% |
| Scopus BioPharma Inc. | 7.45 Million USD | -6.589% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 98.393% |
| Statera Biopharma, Inc. | 22.67 Million USD | 64.961% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | 27.198% |
| Trevena, Inc. | 48.26 Million USD | 83.537% |
| Vaxxinity, Inc. | 30.94 Million USD | 74.323% |
| Vaccinex, Inc. | 5.94 Million USD | -33.719% |
| Vicapsys Life Sciences, Inc. | 1.96 Million USD | -303.67% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | 79.294% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -187.721% |